dal-GenE

Objective

A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular risk in a genetically defined population with a recent Acute Coronary Syndrom (ACS): The dal-GenE Trial. The purpose of this study is to evaluate the potential of dalcetrapib to reduce cardiovascular morbidity and mortality in subjects with a documented recent Acute Coronary Syndrome and the AA genotype at variant rs 1967309 in the ADCY9 gene.

Location:

Essentia Health Duluth

Disclosures:

None

For more information about a financial conflict of interest (FCOI), review the Essentia Health FCOI policy.

Last Updated: 06/23/2016

Research Study Categories

• Adult Studies

Specialty

• Cardiology

Contact

Clinical Trials at 866-839-4128
or clinicaltrials@eirh.org